Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 29;11(9):1349–1356. doi: 10.14202/vetworld.2018.1349-1356

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Prihatno, et al.

Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Figure-5 — Vimentin immunoreactivity after secretome injection (immunohistochemistry; 500× magnification). In the low-dose group (A1), 1 week after the first secretome injection, a strong vimentin immunoreactivity was observed in the spermatozoa (yellow arrow) and Sertoli cells (blue arrow), whereas in the high-dose (A2) group, the immunoreactivity was moderate. In the low-dose group (B1), 1 week after the second secretome injection, a strong vimentin immunoreactivity was still observed in the spermatozoa and Sertoli cells. Meanwhile, in the high-dose group (B2), the immunoreactivity was very strong in the same cell. In the low-dose group (C1), 1 week after the third secretome injection, moderate vimentin immunoreactivity was observed in the spermatozoa and Sertoli cells, whereas in the high-dose group (C2), the immunoreactivity was strong in the same cells. Then, 1 week after the last injection in the high-dose group (D1), the vimentin immunoreactivity was moderate in the spermatozoa and Sertoli cells. Spermatogonia (red arrow), primary spermatocytes (green arrow), and Leydig cells (white arrow).